MARK
ALLEN |
University
of Florida College of Pharmacy |
| Major
|
Social &
Administrative Sciences |
| GPA: |
3.974/4.0 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To create
an instrument that can accurately measure medication affordability
for patients in order to address the problem of patients using
less medication than prescribed to reduce out-of-pocket costs.
My research is on improving medication affordability for those
who currently report that they use less medication than prescribed
solely because of cost. |
| Title
of Dissertation: |
“Development
and Validation of the 'Medication Affordability Scale' |
| Degrees
Received: |
M.A., Sociology,
University of Florida, May 2007,
B.A., Mathematics, University of California at Berkeley, May 1991
|
| Honors
Received: |
2006, 1st
Place Poster, UF Department of Health Services Research Fair;
Gordon and Ruth Streib Award for outstanding paper written by
a graduate student, University of Florida Department of Sociology
|
| AFPE
Award: |
American
Society of Health - Systems Pharmacists Foundation - AFPE Pre-Doctoral
Fellowship in the Pharmaceutical Sciences |
|
DAVID
G. ANDERSON |
University
of Iowa College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA: |
4.0/4.0 |
| Graduation
Date: |
August 2010 |
| Focus
of Research: |
To characterize
oxidative metabolites of dopamine potentially implicated in Parkinson’s
disease (PD) by establishing conditions suitable for synthesis
of the quinone derivative of DOPAL, characterizing the reactivity
of this compound toward relevant cellular and protein nucleophiles,
as well as structural determination of any resultant adduct products.
Parkinson’s Disease involves selective death of dopaminergic
neurons. Dopamine and its metabolites, such as 3, 4-dihydroxyphenylacetaldehyde
(DOPAL), are known to be neurotoxic and are hypothesized to play
a role in the disease pathogenesis. DOPAL is an aldehyde formed
via oxidative deamination of dopamine catalyzed by monoamine oxidase.
Dopamine’s ability to autooxidize to a quinone is proposed
to contribute to its toxicity, namely through mechanisms such
as redox cycling and protein modification. DOPAL is even more
toxic than dopamine, but its ability to auto-oxidize to a quinone
and the biological significance of such oxidation are unknown.
There is the potential that information gained in this research
will allow the presence and/or importance of DOPAL quinones in
PD to be established. The goal of the research is to identify
new therapeutic agents to elucidate mechanisms involved in the
pathogenesis of Parkinson’s Disease. |
| Title
of Dissertation: |
“Protein
Modification by Oxidized Derivatives of Dopamine and Dopamine
Metabolites in Regards to Parkinson’s Disease and Neurodegenerative
Disorders.” |
| Degrees
Received: |
B.S., Chemistry,
Exercise Science, Elmhurst College, June 2005 |
| Honors
Received: |
2007, Endowed
AFPE Pre-Doctoral Fellowship; 2007-2006, University of Iowa Center
for Biocatalysis and Bioprocessing Fellowship; 2007, University
of Iowa Student Government Scholarly Presentation Award, University
of Iowa Graduate Student Senate Travel Fund Scholarship; 2006-2005,
Medicinal and Natural Products Chemistry Division Fellow; 2005,
Rudolf J. Priepke Scholastic Achievement Award in Chemistry, M.
Eileen Hackman Student Achievement Award in Kinesiology, Elmhurst
College Ranking Scholar; 2005-2004, Lloyd J. Palmer Nalco Chemical
Co. Endowed Scholarship; 2005-2000, Elmhurst College Presidential
Scholarship |
| AFPE
Award: |
Ernest Mario
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
CHASITY D. ANDREWS |
| University
of Michigan College of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
4.08/4.30 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To investigate
the mechanism of action of a molecular adjuvant, cytosine phosphate
guanine (CpG) oligodeoxynucleotides (ODNs), through the use of
a potential new vaccine delivery system that targets CpG ODNs
to the endosome. This research is focused on generating a vaccine
delivery system to stimulate a strong cell-mediated immune response,
which is effective at clearing virally infected cells.. |
| Title
of Dissertation: |
“Multicomponent
Vaccine Delivery System: Subcellular Targeting of Antigen and
Molecular Adjuvant” |
| Degrees
Received: |
B.S., Chemistry,
University of North Carolina-Chapel Hill, May 2003 |
| Honors
Received: |
2008-2006,
NIH Cellular Biotechnology Training Program Fellowship; 2003,
Graduated with Honors in Chemistry, Hypercube Scholar, Graduated
with Distinction |
| AFPE
Award: |
Josiah Kirby
Lilly Sr. Memorial - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
CHARLENE A. BAKSH |
University
of Maryland at Baltimore School of Pharmacy |
| Major
|
Applied Clinical
Pharmacology (Pharmacometrics) |
| GPA:
|
3.91/4.0 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To develop
a pharmacokinetic-pharmacodynamic model, and subsequently, simulate
treatment regimens or trials which will be able to predict concentrations
and effects of an investigational chemotherapeutic agent, UCN-01.
Being able to characterize the pharmacodynamic aspects of drug
candidates is essential for an entity t o be therapeutically successful. |
| Title
of Dissertation: |
“Population
Pharmacokinetic and Pharmacodynamic Modeling and Simulation of
the Investigational Anticancer Agent, UCN-01” |
| Degrees
Received: |
Pharm.D.,
University of Maryland at Baltimore, May 2004 |
| Honors
Received: |
2007 AFPE
Pre-Doctoral Fellowship; 2006, AFPE Pre-Doctoral Fellowship; 1999,
Outstanding Academic Achievement as a Sophomore |
| AFPE
Award: |
The Merck
Company Foundation Endowed - AFPE Pre-Doctoral Fellowship in the
Pharmaceutical Sciences |
LAURA N. BONIFACIO |
University
of North Carolina at Chapel Hill School of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
N/A |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To demonstrate
a specific role for miRNA in the aging process and elucidate the
mechanisms in which these miRNAs are regulated. As we begin to
define the role of miRNAs in physiology and pathological processes
as well as the mechanisms of miRNA regulation, our understanding
of cancer and other age-related diseases will enable rational
drug design and more accurate methods of diagnosis. To date, our
knowledge of the process of aging is incomplete and offers no
comprehensive explanation of a role for miRNA in this process
despite the fact that such a role seems likely. |
| Title
of Dissertation: |
“Defining
the Role and Regulation of miRNA in Aging and Age Related Diseases" |
| Degrees
Received: |
Pharm.D.,
University of North Carolina at Chapel Hill, December 2005 |
| Honors
Received: |
2008, AFAR-GSK
Fellow; 2007 Fred Eshelman-Endowed AFPE Fellow; 2006-2005, Sibyl
Vorheis Jennings Memorial Scholarship; 2006-2004, Sibyl Vorheis
Jennings Memorial Scholarship; 2005, Fred Eshelman Scholarship,
Jacobs Award in Medicinal Chemistry; 2004, Jeffery M. Jordan Memorial
Scholarship |
| AFPE
Award: |
Fred Eschelman
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
LISA A. BONNER |
Purdue University School of Pharmacy and Pharmaceutical Sciences |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
3.88/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To design
and synthesize dopamine receptor agonists that are conformationally
rigid analogues of dopamine and mimic its orientation in the binding
site of each of five different dopamine receptors in order to
study the functional importance of each unique class of dopamine
receptors. Dopamine transmission is important in several major
biological pathways, including reward circuits, memory consolidation,
locomotor control. Studying the action of dopamine within these
pathways can offer insights into normal function, as well as diseases,
like addiction, schizophrenia, and Parkinson’s disease |
| Title
of Dissertation: |
“Design
and Synthesis of Potential Dopamine D1 Selective Ligands—Molecular
Exploration of Hydrogen-Bonding Networks in D1 versus D2 Dopamine
Receptors” |
| Degrees
Received: |
B.S., Biochemistry/Chemistry,
Loyola College in Maryland, May 2002 |
| Honors
Received: |
2007, Endowed
AFPE Pre-Doctoral Fellowship; 2006, Purdue University Graduate
Student Award for Outstanding Teaching; 2005, Albert and Anna
Kienly Award for Excellence in Teaching; 2003, Ross Fellowship;
2001, Dean’s Academic Scholarship, Phi Beta Kappa, Hauber
Summer Research Fellowship; 1998, Presidential Academic Scholarship |
| AFPE
Award: |
Pfizer Inc.
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
MARK P. BORGMAN |
University
of Maryland, Baltimore School of Pharmacy |
| Major
|
Pharmaceutical
Sciences |
| GPA:
|
3.81/4.00 |
| Graduation
Date: |
August 2009 |
| Focus
of Research: |
The targeted
delivery of bioactive agents to solid tumors using novel polymeric
biomaterials. The targeted delivery system is aimed to significantly
improve the therapeutic index and efficacy of potent anti-cancer
drugs. The ability to selectively target therapeutic agents to
tumor tissue using polymeric systems reduces non-specific toxicity
and is a strategy that holds promise for creating new successful
treatments for cancer. |
| Title
of Dissertation: |
“Tumor-targeted
Delivery of Chemotherapeutics Using HPMA Copolymer-RGDfK Conjugates” |
| Degrees
Received: |
B.S., Medical
Technology, Michigan State University, May 2004 |
| Honors
Received: |
2007, AFPE
Pre-doctoral Fellowship Award; 2007, U of Maryland Graduate Student
Fellowship; 2006 AFPE Pre-doctoral Fellowship Award; 2004, Academic
Honors Michigan State University Medical Technology; 2004-2003,
Dean’s Honor Roll |
| AFPE
Award: |
The Merck
Company Foundation Endowed - AFPE Pre-Doctoral Fellowship in the
Pharmaceutical Sciences |
GARY E. BRANDT |
The
University of Kansas School of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To validate
that natural products and natural product derived compounds are
a valuable resource for drug development by taking cruentaren
A and gendrunin, two natural products with anti-cancer activity,
and demonstrating their transformation from natural product to
drug. As a platform for drug discovery, the use of natural products
is well validated as a source of chemical leads. In an effort
to develop drug candidates for the successful treatment of cancer,
these two small molecule natural products have been selected for
further development. Cruentaren A selectively inhibits F1Fo ATP
Synthase and a highly convergent total synthesis is being pursued
for library development. Gedunin is a novel Hsp90 inhibitor for
which a mechanism of action has yet to be determined. Semi-synthetic
modification of gedunin is being accomplished to generate compounds
which can help elucidate the mechanism by which gedunin binds
Hsp90 and in order to develop more potent inhibitors |
| Title
of Dissertation: |
“Natural
Products as Lead Compounds in Drug Discovery: Total Synthesis
and Structure Activity Relationship Studies of Cruentaren A, and
Structure Activity Relationship Studies of Gedunin via Semi-Synthesis
for the Development of Novel Cancer Chemotherapeutic Agents Targeting
F1Fo ATP Synthase and Hsp90 Respectively"” |
| Degrees
Received: |
B.S., Chemistry,
Georgia State University, December 2005 |
| Honors
Received: |
2007, Guest
Speaker at KU Relay for Life; 2006, Self Graduate Fellowship Recipient;
2005, Best Presentation in Biochemistry at SECURE, Faculty Scholarship
Award; 2005-2004, Organic Chemistry Student of the Year; 2004
Dean Scholarship Key; 2000, Robert C. Byrd Scholarship |
| AFPE
Award: |
GlaxoSmithKline
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
ADAM J. COLE |
University
of Michigan – Ann Arbor College of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
4.05/4.30 |
| Graduation
Date: |
April 2008 |
| Focus
of Research: |
To demonstrate
the feasibility of a multi-component delivery system to deliver
RNAi therapy to brain tumors. The system will consist of a magnetically
targeted magnetic iron oxide nanoparticle (MION) coupled to tumor
specific siRNA. In order to ensure tumor-specific internalization
of siRNA (necessary for RNAi function), a prodrug-like strategy
will be integrated. MRI visibility of MION will be exploited to
provide a quantitative, non-invasive monitoring of delivery system
pharmacokinetics and biodistribution. A MION-RNAi delivery system
could offer an exciting new rout to deliver RNAi to the brain |
| Title
of Dissertation: |
“
Magnetically Delivered RNAi Therapy for the Treatment of Brain
Tumors" |
| Degrees
Received: |
M.S., Pharmaceutics,
University of Michigan – Ann Arbor, April 2007,
B.S. in Engineering, Chemical Engineering, University of Michigan
– Ann Arbor, April 2004 |
| Honors
Received: |
2008, AFPE
Pre-Doctoral Fellowship; 2007-2006, NIH PSTP Fellowship; 2005,
Warner-Lambert/Parke Davis Fellowship; 2004, Phi Kappa Phi National
Honor Society; 2003, UM Lloyd Kempe Biochemical Engineering Scholarship,
UM Helen Gibson Chemical Engineering Scholarship, UM Nicholas
Chemical Engineering Scholarship, 2002, UM Bryner Williams Chemical
Engineering Scholarship, UM Bandemer Engineering Scholarship,
2000, University of Michigan Regents Scholarship p |
| AFPE
Award: |
Ernest Mario
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences.
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
JAMES R. DAVIS |
University
of Utah College of Pharmacy |
| Major
|
Pharm. D./Ph.D.
Pharmaceutics and Pharmaceutical Chemistry |
| GPA:
|
3.8/4.0 |
| Graduation
Date: |
May 2011 |
| Focus
of Research: |
To induce
proteasomal degradation of disease-causing proteins. This research
aims to accomplish this task by creating fusion proteins with
signal sequences (nuclear localization and nuclear export signals),
the estrogen receptor ligand-binding domain, and a dimerization
domain. When this protein is introduced into a cell; the dimerization
domain is capable of dimerizing with a native disease-causing
protein of interest. Proteasomal degradation is induced by the
addition of the pure antiestrogen fulvestrant, known to cause
proteasomal degradation of wild-type estrogen receptor. Degrading
these disease-causing proteins should rescue the cell from the
deleterious effects seen when the protein is present. |
| Title
of Dissertation: |
“Controlled
Proteasomal Degradation of Disease-Causing Proteins" |
| Degrees
Received: |
Pharm.D.,
University of Tennessee College of Pharmacy, May 2005
B.A., Biology, University of Northern Iowa, May 2001 |
| Honors
Received: |
2006, GlaxoSmithKline-AFPE
Pre-Doctoral Fellowship, AFPE Pharmaceutical Sciences Graduate
Student Recognition Award; 2005, Valedictorian, University of
Tennessee College of Pharmacy, Lilly Achievement Award, Medicinal
Chemistry Award; 2004-03, Seldon D. Feurt Memorial Scholarship;
2002, Plough Scholarship, University of Northern Iowa Merchant
Scholarship; 2001, Seldon D. Feurt Scholar (PharmD/PhD Scholarship),
University of Northern Iowa Purple and Old Gold Award |
| AFPE
Award: |
Josiah Kirby
Lilly Sr. Memorial - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
ADAM S. DUERFELDT |
The
University Of Kansas School of Pharmacy |
| Major
|
Pharmaceutical
Science |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
May 2011 |
| Focus
of Research: |
To design
chemotherapeutical analogs with an improved pharmacokinetic and
pharmacodynamic profile with increased potency. My hypothesis
is that chimeric, conformationally restrained molecules containing
acis-amide orientation are predisposed to the bent conformation
and will exhibit a higher affinity for Hsp90 due to the entropic
penalty. Testing this hypothesis will also allow me to engineer
analogs to optimize beneficial interactions in the binding pocket.
Previous research has shown that Hsp90 binds adenosine-5'-triphosphate
(ATP) in an unusual, bent conformation. Similarly, the protein
binds two cytotoxic antibodies, geldanamycin and radiciol, in
the same bent conformation with high affinity. These two antibiotics
however, reveal undesired toxicities due to certain functional
groups. Our lab has previously shown that chimeric, seco, derivates
of goldanamycin and radicicol show high affinity for Hsp90 while
eliminating the toxic functional groups found in the natural products.
Through many cocrystallization experiments, it has been shown
that when Hsp90 binds the antibodies, the trans-amide bond is
isomerized into a cis-amide orientation. This isomerization occurs
with an entropic penalty |
| Title
of Dissertation: |
“The
Synthesis and Biological Evaluation of Chimeric, Conformationally
Biased Hsp90 Nterminal Inhibitors" |
| Degrees
Received: |
B.A., Chemistry,
Central College of Iowa, May 2006 |
| Honors
Received: |
2006-2002,
Central College Dean's List; 2006-2004, COSIDA Academic All-Conference,
COSIDA Academic All-District; 2006-05, ESPN Magazine First Team
Academic All-American; 2006, ESPN Magazine Academic All-American
of the Year, IIAC Duane Schroeder Scholar of the Year, Woody Hayes
National Scholar Athlete of the Year, Summa Cum Laude, Alpha Zeta
Mu Inductee |
| AFPE
AWARD: |
Josiah Kirby
Lilly, Sr. Memorial - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
MICHAEL E. DUNN |
University
of Rhode Island College of Pharmacy |
| Major:
|
Pharmacology/Toxicology |
| GPA:
|
3.7/4.0 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
The research
focus is the skeletal muscle, specifically skeletal muscle HIF-1a,
as an early diagnostic indicator of preclinical heart failure
that eludes current diagnostic techniques such as EKG analysis.
Through the development of a decreased cardiac output mouse model,
achieved through thoracic aortic banding, the research intends
to show the pathological progression in the skeletal muscle, as
well as the upregulation of HIF-1a, through time, in a time course
evaluation of the progression and transition from a healthy to
a failing heart. With the progression of heart failure, it is
known that skeletal muscle perfusion decreases. HIF-1a, a transcription
factor that serves as a primary regulator of oxygen homeostasis
in cardiac and skeletal muscle, has not been evaluated in the
skeletal muscle of preclinical and overt heart failure models.
This research has the potential to provide valuable diagnostic
direction in the treatment of early and late-stage heart failure
and to open the door to the development of therapeutics aimed
at attenuating or inhibiting the skeletal muscle morbidities associated
with, and that ultimately progress to, heart failure. Heart failure
is defined by a decrease in cardiac output preceded by cardiac
hypertrophy and left ventricular dysfunction, which results from
an increased hemodynamic burden. |
| Title
of Dissertation: |
“Biochemical
and Structural Characteristics of Skeletal Muscle in Association
with HIF-1a Upregulation as Indicators of Sub-clinical Heart Failure” |
| Degrees
Received: |
M.S., Kinesiology,
University of Rhode Island, May 2006
B.S., Biology, University of Vermont, May 2003 |
| Honors
Received: |
2007, AFPE
Pre-doctoral Fellowship; 2006, 3rd Place Poster, Graduate Division;
2003, College Honors at the University of Vermont; 2000, Dean’s
List at the University of Vermont |
| AFPE
Award: |
Wyeth - AFPE
Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
SARAH J. FARNSWORTH |
University
of Utah College of Pharmacy |
| Major
|
Neuroscience |
| GPA:
|
3.95/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
This research
will hypothesize that the neuroprotective properties of DAT inhibitors
is a function of each respective drug’s effect on DA sequestration
by vesicular monoamine transporter (VMAT-2) activity and its actions
at dopaminergic and muscarinic receptors. This hypothesis will
be investigated by conducting experiments to: 1) determine if
muscarinic receptors regulate the effects of methlyphenidate (MPD)
on VMAT-2 mediated DA transport and VMAT-2 intraneuronal distribution,
2) identify if changes in GABAergic activity is the mechanism
underlying cholinergic regulation of DA neurotransmission and
VMAT-2 activity following DAT inhibitor administration, and, 3)
compare the effects of DAT inhibitors with anticholinergic properties
(cocaine, bupropion) versus a DAT inhibitor with no anticholinergic
properties (GBR 12909) on various DAergic parameters. This research
is of great significance, since the results of these drugs on
the VMAT-2-mediated DA transport may contribute to our understanding
of disorders such as ADHD, Parkinson’s disease, and substance
abuse. |
| Title
of Dissertation: |
“Molecular
Mechanisms Underlying Psychostimulant-induced Vesicle Trafficking
and DA Sequestration: Implications for Neurotoxicity and Neurodegenerative
Disorders” |
| Degrees
Received: |
B.S., Summa
Cum Laude, Psychology, Weber State University, May 2004 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship, 2004, Weber State University; 2003, Denkers
Family Undergraduate Research Fellow Award; 2000, F. Ann Milner
Presidential Scholarship Award, Utah State Board of Education
Certificate of Outstanding Academic Performance, President’s
Education Award, National Honor Society Academic Excellence Award
|
| AFPE
Award: |
Ortho-McNeil
Janssen Scientific Affairs - AFPE Pre-Doctoral Fellowship in the
Pharmaceutical Sciences |
AMANDA M. FENNER |
University
of Iowa College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
December
2010 |
| Focus
of Research: |
To design,
synthesize, and evaluate structurally diverse derivatives of naturally
occurring amino sugars as novel inhibitors of host-pathogen interactions.
The research will employ carbohydrate chemistry in the design
and synthesis of anti-infective and anti-cancer agents. By beginning
synthesis from small oligosaccharides, binding assays will be
employed to determine which sulfation and N-acyl patterns yield
highest selectivity and affinity for heparan sulfate-binding pathogen
surface proteins and heparanase inhibition. Ultimately, the oligosaccharide
derivatives that selectively bind bacterial surface proteins will
be used as chemical probes to study heparan sulfate binding versus
heparan sulfate bridging mechanisms in bacteria-host cell interactions
and to design potential inhibitors based on the effect on viability
of these two different host-pathogen interactions. |
| Title
of Dissertation: |
“Heparan
Derivatives that Bind and Block Host-Pathogen Interactions as
Anti-Infectives and Anti-Cancer Therapeutics" |
| Degrees
Received: |
B.A., Chemistry,
Central College, May 2005 |
| Honors
Received: |
2008-2007,
Research Training Program in Panama; 2007, Pharmacological Sciences
Training Grant Trainee, U of Iowa Graduate Research Assistant;
2006, U of Iowa Teaching Assistant, Luther College Jenson Medal,
ACS Senior Chemistry Student Award; 2005, John G. & Mildred
Breiland Scholarship, Luther Community Scholarship; 2005-2002,
Luther Regent Scholarship; 2002, American Business Women's Scholarship |
| AFPE
Award: |
PhRMA Foundation
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
|
|
DANIEL P. FLAHERTY |
University
of Nebraska Medical Center Collegeof Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
June 2010 |
| Focus
of Research: |
To establish
a structure-activity relationship (SAR) for bis-styrylbenzenes
in the binding to and inhibition of aggregation of amyloid-B,
a key pathogenic peptide in Alzheimer’s Disease (AD). The
research will synthesize target compounds and test them in biological
assays to determine binding contrasts to amyloid-B fibrils. Based
on this data, new sets of compounds will be designed to optimize
amyloid-B binding and efficacy against amyloid-B aggregation and
cell death. The research hypothesis is that styrylbenzene derivatives
will inhibit the aggregation of amyloid-B filaments andoligomers,
and exhibit a protective effect by inhibition of amyloid-B induced
neurotoxicity in neuronal cells. It is anticipated that unsymmetrical
compounds will possess increased solubility, which will lead to
better efficacy and ADME profiles. |
| Title
of Dissertation: |
“Styrylbenzenes
as Potential Therapeutics for Alzheimer’s Disease.” |
| Degrees
Received: |
B.A., Suma
Cum Laude, Chemistry, Central College, May 2005 |
| Honors
Received: |
2008, Harris
Award for Research in Alzheimer's Disease (AD), Nancy and Ronald
Reagan Award for Research in Alzheimer’s Disease; 2007,
AFPE Pre-Doctoral Fellowship; 2005, Outstanding Senior Chemist,
Top Male Athlete GPA, Central College Baseball Ver Steeg Award |
| AFPE
Award: |
Ortho-McNeil
Janssen Scientific Affairs - AFPE Pre-Doctoral Fellowship in the
Pharmaceutical Sciences |
KEVIN J. FREISE |
University
of Iowa College of Pharmacy |
| Major
|
Pharmaceutics |
| GPA: |
4.0/4.0 |
| Graduation
Date: |
August 2009 |
| Focus
of Research: |
To create
a mechanically based pharmacokinetic/pharmacodynamic mathematical
model of the relationship between erythropoietin and erythropoiesis
in critically ill neonatal infants in order to optimize treatment
of anemia with erythropoietin in these infants. The goal of the
research is to use PK/PD modeling and simulation to optimize drug
therapy and to improve the design and analysis of both preclinical
and clinical studies. |
| Title
of Dissertation: |
“Mechanically
Based Pharmacokinetic/Pharmacodynamic Analysis of Erythropoiesis
and Erythropoietic Compounds.” |
| Degrees
Received: |
M.S., Veterinary
Medical Science, University of Illinois at Urbana-Champaign, May
2004
B.S., Animal Science, University of Illinois at Urbana-Champaign,
December 2001 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellow; 2005, Presidential Graduate Fellow; 2002,
Bronze Tablet Award; 2002-1998 Edmund J. James Scholar; 2001,
Senior 100 Honorary; 2000, 1st Place Invitational Research paper
at Undergraduate Paper Competition for Midwest American Society
of Animal Sciences, J. Baldwin Turner Undergraduate Research Grant |
| AFPE
Award: |
United States
Pharmacopeia (USP) - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
JASON M. FRITZ |
University
of Colorado Denver School of Pharmacy |
| Major
|
Pharmacology/Toxicology
|
| GPA: |
3.98/4.0 |
| Graduation
Date: |
June 2011 |
| Focus
of Research: |
To investigate
the interactions of non-small cell lung cancer and the alveolar
macrophage, a key effector of chronic lung inflammation. Tumor-associated
macrophages appear to promote lung carcinogenesis, and elucidating
the mechanistic interactions between these cell types may yield
new vectors for pharmacological therapy, as well improve current
detection screening. Understanding the important protein and lipid
signaling factors that allow a tumor to benefit from increased
macrophage presence may lead to new therapeutic target that could
be manipulated pharmacologically, and so doing, inhibit lung carcinogenesis. |
| Title
of Dissertation: |
“Tumor-Educated
Alveolar Macrophages Augment Lung Tumorigenesis" |
| Degrees
Received: |
B.S., Summa
Cum Laude, Biochemistry, University of Denver, June 2005 |
| Honors
Received: |
2005, Phi
Beta Kappa induction; 2005-2003, Dean's List and Hornbeck Scholar;
2004, A.C.S. Analytical Chemistry Award; 2003, Chemical Rubber
Company Chemistry, Honorable discharge from U.S.M.C.; 1997, U.S.N.
commendation for Scholastic Ability |
| AFPE
Award: |
Johnson &
Johnson Pharmaceutical R&D - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
ERIN M. GAGAN |
University
of Iowa College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA: |
3.84/4.0 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To determine
the mechanisms of toxicity of molinate, a thiocarbamate herbicide,
and dieldrin, an organochlorine pesticide. This project aims to
provide information regarding the structure-activity relationship,
the cellular targets, and evaluation of adverse cellular effects
from exposure to these two compounds with the goal of gaining
insight into possible therapeutic targets and new methods of preventing
adverse effects from exposure to these compounds. In addition,
this research could elucidate biomarkers for earlier detection
of idiopathic Parkinson’s Disease which has been linked
to pesticide exposure, as well as develop methods to prevent Parkinson’s
Disease resulting from dieldrin exposure. |
| Title
of Dissertation: |
“Mechanisms
of Toxicity and Structure-Activity Relationships of Molinate and
Dieldrin" |
| Degrees
Received: |
B.S., Biology,
Ashland University, May 2006 |
| Honors
Received: |
2007, Outstanding
Poster Presentation, CS SOT; 2006, Ohio Board of Reagents Fellowship,
Senior Academic Honors Award, Biology Department; 2006-2002, Dean's
List, Presidential Scholarship, Music Scholarship, Scholars Test
Scholarship |
| AFPE
Award: |
GlaxoSmithKline
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
AMBER M. GOEDKEN |
University
of Iowa College of Pharmacy |
| Major
|
Social &
Administrative Sciences |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To determine
the impact of drug benefit plan structures on medication use and
health outcomes, particularly in terms of how cost-sharing affects
the use of medications by elderly Medicare beneficiaries. Given
that the Medicare drug benefit will provide drug coverage for
millions of seniors well into the future, it is important to understand
how cost-sharing affects their decisions about what medicines
to use. Armed with this information, pharmacists may be able to
help patients select the coverage that best meets their needs. |
| Title
of Dissertation: |
“Impact
of Cost-Sharing on Prescription Medication Use and Hospitalizations
Among Elderly Medicare Beneficiaries with Congestive Heart Failure
in Stand-Alone Medicare Prescription Drug Plans” |
| Degrees
Received: |
Pharm.D.,
University of Iowa, May 2004 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2007, Outstanding Teaching Assistant
Award, 3rd Place in Biological & Health Science Division at
the James F. Jakobsen Graduate Conference; 2005, AACP Wal-Mart
Scholarship |
| AFPE
Award: |
American
Society of Health-System Pharmacists - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
DAVID J. GOOD |
University
of Michigan College of Pharmacy |
| Major: |
Pharmaceutics |
| GPA: |
4.06/4.30 |
| Graduation
Date: |
March 2010 |
| Focus
of Research: |
To determine
the mechanisms by which moisture can generate pharmaceutical cocrystals
when solid particles of cocrystal reactants are exposed to moisture
rich conditions. This project involves understanding the thermodynamic
and kinetic principles associated with the phase transformations
as solid blends evolve into solutions which lead to crystallization
or dissolution of cocrystals. These parameters are critical to
formulating stable solid dosage forms of cocrystals. |
| Title
of Dissertation: |
“Determination
of the Kinetics, Thermodynamics, and Mechanisms of Moisture Induced
Phase Transformations relating to the Formation and Stability
of Pharmaceutical Cocrystals” |
| Degrees
Received: |
M.S., Pharmaceutical
Chemistry, Lehigh University, January 2004
B.S., Chemistry, Allegheny College, May 2001 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship: 2003, ICI Innovation Award; 1999-97,
Alden Scholar |
| AFPE
Award: |
Pfizer Inc.Endowed
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
PETE P. GUERRIERI |
Purdue
University School of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
3.7/4.0 |
| Graduation
Date: |
June 2009 |
| Focus
of Research: |
To investigate
the underlying mechanism governing moisture uptake in pharmaceutical
salts and concomitantly to investigate the physico-chemical state
of water at the surface including in the presence of excipients.
The goals are to obtain a more comprehensive definition of the
term hygroscopicity, to better understand the specific phenomena
responsible for chemical and physical instability and finally
to apply the knowledge gained to predict the interaction of pharmaceutical
salts with various types of excipients and how this impacts chemical
stability. Various surface analytical techniques will be explored
in relation to these goals. Despite the well-known detrimental
effect of moisture on stability of many pharmaceutical active
ingredients, to date a firm molecular-level mechanistic understanding
of the processes involved in both moisture uptake and resultant
chemical reactivity has not been realized. |
| Title
of Dissertation: |
“Investigation
of the Fundamental Basis of Hygroscopicity in Pharmaceutical Salts
and the Consequent Impact on Physical and Chemical Stability” |
| Degrees
Received: |
B.Sc., Chemical
Engineering, Minor in Chemistry, Widener University, May 2003 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2003, American Chemical Society Award
for Chemical Engineering, 2003-2002, Member of Tau Beta Pi and
Sigma Pi Honor Societies, 2003-1999, Dean’s List |
| AFPE
Award: |
Pfizer Inc.
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
IGOR GUREVICH |
University
of Connecticut Storrs School of Pharmacy |
| Major
|
Pharmacology/Toxicology |
| GPA:
|
3.76/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To provide
a tool for understanding the physiological and pharmacologic activity
of retinoids and perhaps provide a novel pharmacological approach
to regulating retinoid activity by examining the mechanisms of
interaction between retinoic acid receptors (RARs) and a novel
coregulator recently isolated in our laboratory as well as the
mechanisms of the transcriptional repression exerted by this coregulator
and mechanisms by which the expression of this coregulator is
controlled. Retinoids play an important role in embryonic development,
vision, and maintenance of epithelial tissues. Retinoids are also
used in cancer treatment, particularly acute promvelocytic leukemia
and melanoma |
| Title
of Dissertation: |
“Mechanisms
of Corepressor Recruitment by Nuclear Retinoid Receptors.” |
| Degrees
Received: |
B.S., Food
Science, University of Massachusetts Amherst, May 2000 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2006, AFPE Pre-Doctoral Fellowship; 2006
Boehringer Ingelheim Pharmaceuticals, Inc. Pre-Doctoral Fellowship
in Pharmaceutical Sciences |
| AFPE
Award: |
Johnson &
Johnson Pharmaceutical R&D - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
SHUMET A. HAILU |
University
of Connecticut Storrs School of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
3.94/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
This research
focuses on stabilization and/or destabilization of amorphous drugs
prepared with silicate. The goal is to improve chemical stability
by proper selection of silicates with the required properties
and/or optimization of formulation parameters for optimum drug
stability. The current application of amorphous drugs that can
enhance dissolution rate and bioavailability of poorly soluble
drugs has been limited due to poor physical and chemical stability
as compared to the crystalline forms. Several silicates have been
investigated for use in the preparation of physically stable amorphous
drugs and produced successful results. This study addresses the
chemical stability problem, so as to achieve formulation development
of both chemically and physically stable drugs amorphized with
silicates. |
| Title
of Dissertation: |
“Chemical
Stability of Pharmaceuticals Amorphized with Silicates” |
| Degrees
Received: |
M.S., Pharmaceutics,
Addis Ababa University, Ethiopia, July 2002
B.S., Pharmacy, Addis Ababa University, Ethiopia, July 1998 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2006, USP Fellowship; 2004, University
of Connecticut Graduate School Multicultural Fellowship; 2001,
German Academic Exchange Program Research Fellowship |
| AFPE
Award: |
TEVA Pharmaceuticals
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
WENDY J. HARTSOCK |
University
of Kansas School of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
3.66/4.00 |
| Graduation
Date: |
January 2010 |
| Focus
of Research: |
To focus
on the elucidation of peptidic ligand binding sites in the delta
opioid receptor. Techniques employed in studying these interactions
include MALDI mass spectrometric peptide mapping of affinity labeled
receptors and Western analysis of protein-peptide complexes. The
research involves determination of receptor-ligand interactions
at the molecular level using state-of-the-art analytical techniques.
Structural studies of membrane bound proteins are gaining importance
as these proteins represent a major class of drug targets and
such studies will facilitate the development of novel peptide-based
therapeutics. |
| Title
of Dissertation: |
“Probing
Receptor-Peptide Interactions of the Delta Opioid Receptor Employing
Dual Labeled Peptide Ligands.” |
| Degrees
Received: |
M.S., Pharmaceutical
Sciences, University of Arizona, August 2005
B.S., Chemistry & Zoology, Northern Arizona University, August
2001 |
| Honors
Received: |
2007, Inducted
into American Peptide Society; 2004, NIH Biological Chemistry
Training Grant; 2001, Phi Lambda Upsilon Honorary Nominee, American
Institute of Chemistry Award |
| AFPE
Award: |
National
Association of Boards of Pharmacy (NABP) - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
RYOKO HIRAKAWA |
University
of the Pacific Thomas J. Long School of Pharmacy and Health
Sciences |
| Major: |
Pharmacology/Toxicology
|
| GPA:
|
3.78/4.00 |
| Graduation
Date: |
December
2008 |
| Focus
of Research: |
Investigate
the possible mechanisms underlying the adverse CNS effects associated
with the use of fluoroquinolone antimicrobial agents and non-steroidal-anti-inflammatory
drugs using electrophysiological techniques. This research is
a neuropharmacological investigation of the possible mechanisms
underlying the adverse CNS effects association with the use of
fluoroquinolone antimicrobial agents and non-steroidal, anti-inflammatory
drugs. Ciprofloxacin (fluoroquinolone) is also the first line
treatment for anthrax poisoning and acquiring data establishing
the actions of these clinically important drugs on the nervous
system will facilitate their prevention and/or treatment. |
| Title
of Dissertation: |
“Electrophysiological
Studies of the Interaction between Fluoroquinolone Antibacterials
and NSAIDs at Nerve Cell Receptors and Ion Channels” |
| Degrees
Received: |
M.S., Biological
Sciences (Physiology), San Jose State University, May 2004
B.S., Cum Laude, Biology, Notre Dame de Namur University, May
2001 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2007, Travel Fellowship - IBRO World
Congress of Neuroscience, Member, Japanese Neuroscience Society;
2007-2006, John Shinkai Endowed Graduate Student Scholarship;
1997-2001, Dean’s List |
| AFPE
Award: |
Procter &
Gamble - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
LUCY S. HODGE |
University
of Minnesota College of Pharmacy |
| Major:
|
Pharmacokinetics/Metabolism |
| GPA:
|
3.82/4.00 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To understand
the mechanisms of drug transport within healthy and cancerous
cervical tissue and examine how these mechanisms may affect the
uptake, cytotoxicity, and efficacy of nucleoside analogues used
in the treatment of gynecological cancers. This investigation
will employ human cervical tissue collected from women undergoing
hysterectomies (both cancer and non-cancer specimens) to assess
mRNA and protein levels of cervical equilibrative and concentrative
nucleoside transporters involved in the uptake of nucleoside analogues
such as gemcitabine. The tissue will also be utilized to isolate
membrane vesicles for ex vivo functional transporter studies.
In vitro studies with cervical cell models will be used to study
the contribution of specific transporters involved in the influx
and efflux of nucleoside analogues. The goal is to develop and
utilize various methodologies to understand the mechanisms of
transport of nucleoside analogues, such as gemcitabine, within
cervical tissue. Ultimately, it is hope the research will contribute
to improving upon available therapies for the treatment of gynecological
cancer by examining how localized delivery of radiation-sensitizing
agents may benefit patients by limiting system side effects and
decreasing local cytotoxicity. |
| Title
of Dissertation: |
“Cervical
Delivery and Transport of Gemcitabine for Radiation Sensitization" |
| Degrees
Received: |
Pharm. D.,
Magna Cum Laude, Pharmacy, University of Minnesota College of
Pharmacy, May 2006, B.A., Chemistry, College of Saint Catherine,
May 2002 |
| Honors
Received: |
2003, Melendy
Research Scholarship; 2002, Senior Chemistry Award-College of
Saint Catherine; 2002-1998, Sisters of Alexandria Educational
Scholarship; 2001, Who's Who of American College Students, Phi
Beta Kappa National Honor Society, Iota Sigma Pi Nat'l Honor Society
for Women in Chemistry, 3M Math and Science Scholarship |
| AFPE
Award: |
Johnson &
Johnson Pharmaceutical R&D - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
JILLIAN H. HURST |
University
of Georgia College of Pharmacy |
| Major
|
Pharmacology/Toxicology |
| GPA:
|
3.9/4.0 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To define
the role of RGS proteins in the regulation of Lysophosphatidic
Acid (LPA) signaling in ovarian cancer cells. LPA is the predominant
growth factor in ovarian cancer, driving proliferation, invasion,
and metastasis of cancer cells. Delineating the mechanism and
specificity of RGS regulation of LPA signaling pathways in ovarian
cancer may allow for the rational design of agents to target pathways
with greater specificity than achieved by targeting the receptors
themselves. The effects of LPA are transduced through cell surface
receptors coupled to heteotrimeric G-proteins. While LPA receptors
function by activating G-proteins, the more recently discovered
RGS proteins perform the reciprocal function of deactivating g-proteins.
RGS proteins have been shown to have profound effects on the kinetics
and magnitude of in vivo receptor signaling pathways. Further,
most RGS proteins display specifically for a subset of G-proteins,
and in some cases RGS proteins only deactivate g-proteins that
are coupled to specific receptors. |
| Title
of Dissertation: |
"Characterization
of RGS Regulation of Lysophosphatidic Acid Signaling Pathways
in Ovarian Cancer Cells" |
| Degrees
Received: |
B.S., Chemistry,
Mary Washington College, May 2004 |
| Honors
Received: |
2007 AFPE
Pre-Doctoral Fellowship; 2007, Department Graduate Student of
the Year, Blue Key Honor Society, Achievement Rewards for College
Scientists Foundation; 2006 AFPE Pre-Doctoral Fellowship; 2006,
Medical College of Georgia/University of Georgia Seminar Exchange
Award for Excellence, ASPET Graduate Student Travel Award, Sigma
Xi Member; 2005, University-wide Outstanding Teaching Assistant;
2004-2003, Chi Beta Phi Science Honor Society; 2000, Mary Washington
College Alumni Scholar |
| AFPE
Award: |
TEVA Pharmaceuticals
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
NAISSAN HUSSAINZADA |
University
of Maryland at Baltimore College of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
3.8/4.0 |
| Graduation
Date: |
June 2009 |
| Focus
of Research: |
Defining
the structure, function relationship, and transport mechanisms
of bile acid transport via apical sodium-dependent bile acid (ASBT)
transporter SLC10A2, an enteric solute transporter found to be
physiologically critical during cholesterol homeostasis. Based
upon its intimate link to cholesterol, ASBT has become a novel
pharmaceutical target for hypercholesterolemia treatments and
prodrug approaches. Moreover, this high affinity, high capacity
transporter demonstrates clinically viable utility in prodrug
approaches aimed at increasing oral bioavailability of poorly
absorbed drug entities. However, the efficacy of these stratagems
relies on comprehensive characterization of ASBT transport mechanism(s)
and that is the purpose of this research. |
| Title
of Dissertation: |
“Molecular
Insight Into Transport Mechanisms of the Apical Sodium-Dependent
Bile Acid Transporter" |
| Degrees
Received: |
B.A., Biology,
St. Mary’s University of Maryland, June 2001 |
| Honors
Received: |
2007 AFPE
Pre-Doctoral Fellowship; 2007, University of Maryland Merit Award,
2006-2004, Dean’s List; 2004, Shire Labs Innovative Young
Scientists Award; 1998-1997, Dean’s List |
| AFPE
Award: |
AFPE 21st
Century Club Alumni & Friends - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
PATRICE L. JACKSON |
Howard
University School of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
3.96/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To demonstrate
that a novel series of benzyne sulfonamide enaminones will act
as potential probes for the mechanism of action for anticonvulsant
activity. We anticipate these benzene sulfonamide enaminones will
demonstrate antiepileptic activity in electrically induced seizures
using MES test and in chemically induced seizures using the subcutaneous
pentylenetetrazol (scPTZ) test. These tests are predictive of
generalized tonic-clonic seizures, (MES) or petit mal seizures
(scPTZ), respectively. The preliminary pharmacological testing
of the synthesized compounds will be conducted by the Antiepileptic
Drug Development (ADD) Program
In the Epilepsy Branch of the Neurological Disorders Program at
the National Institute of Neurological Disorders and Stroke (NINDS).
There is a need for new chemical entities for the treatment of
epilepsy that provide a greater benefit as regards side effects
and tolerability, even at the expense of efficacy, as compared
to existing antiepileptic agents. |
| Title
of Dissertation: |
“The
Synthesis of a Novel Series of Benzene Sulfonamide Enaminone Derivatives
as Potential Anticonvulsant Agents" |
| Degrees
Received: |
M.Sc., Chemistry,
Tennessee State University, May 2003,
B.S., Chemistry, LeMoyne-Owen College, May 2000 |
| Honors
Received: |
2007 AFPE
Pre-Doctoral Fellowship; 2007, E.A. Bouchet Graduate Honor Society;
2006, AFPE Pre-Doctoral Fellowship; 2006-2003, Chauncey Copper
Scholarship; 2000, Memphis Chemical Association Scholarship; 1999,
National Dean’s List, US Achievement Academy Scholar; 1999-1998,
Dean’s List |
| AFPE
Award: |
American
Association of Pharmaceutical Scientists - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
STEVEN A. KAWAMOTO |
University
of Michigan College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
3.9/4.30 |
| Graduation
Date: |
December
2009 |
| Focus
of Research: |
To identify
peptide and small molecule compounds that disrupt critical protein-protein
interactions in cancer cells by working on two systems: the Survivin/caspase
interaction and the BCL9 catenin interaction. Through the use
of peptide-based probes, the research will develop biochemical
screening assays, screen libraries of compounds, and perform structure-activity
relationship studies to help optimize compounds for binding to
our biochemical target proteins. The research focuses on targeting
specific proteins that are overexpressed or misregulated in cancer
cells. Such proteins often confer a survival advantage to cancer
cells and can lead to invasive phenotypes if left unchecked. Disruption
of key protein-protein interactions in cancer cells may be a more
specific class of anti-cancer therapy with less toxic side effects
than the broad spectrum anti-proliferation agents which target
all rapidly dividing cells. In addition, targeting protein interactions
instead of DNA (ie. Cisplatin) may reduce the possibility of secondary
cancers that result from ant-cancer treatments. |
| Title
of Dissertation: |
“Disruption
of Protein-Protein Interactions in Cancer Using a-Helical Peptides
and Small Molecule Antagonists" |
| Degrees
Received: |
B.S., Chemistry,
Ohio State University, June 2004 |
| Honors
Received: |
2008, Josiah
Kirby Lily, Jr. Memorial AFPE Pre-Doctoral Fellowship; 2007, AFPE
Pre-Doctoral Fellowship, 2004, University Regent’s Fellowship,
Department of Homeland Security Fellowship, Sigma Xi Grant in
Aid of Research; 2004-2003, University Arts and Sciences Honors
Research Scholarship; 2003, MacNevin Memorial Scholarship, Pressey
Honors Research Scholarship; 2002, National Science Foundation
REU Grant |
| AFPE
Award: |
AFPE 21st
Century Club Alumni & Friends - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
TZIPPORAH M. KERTESZ |
University
of Connecticut School of Pharmacy |
| Major: |
Pharmacology/Toxicology |
| GPA: |
4.0/4.0 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To use a
new high-throughput method of metabonomics to identify the complex
causes of multiple sclerosis (MS) induction and progression. Cerebrospinal
fluid from the rat model of myelin oligodendrocyte induced Experimental
autoimmune encephalomyelitis will be analyzed to identify biomarkers
of disease induction and progression. Samples from patients suffering
from MS will be compared to the rat samples in order to correlate
the animal model to the human disease. The identity of the biomarkers
will be used to explore the metabolic pathways altered in MS in
order to further understand of the mechanisms of the disease and
the opportunity for improved therapeutics. Metabonomics can be
a powerful technique for analyzing the efficacy of drugs, the
metabolism of drugs, the progression of disease, and idiosyncratic
reactions as well as a fast tool for identifying new pathways
that can be targeted for different disease states. |
| Title
of Dissertation: |
“A
Metabonomic Analysis of Multiple Sclerosis: The Role of Polyamines
in Multiple Sclerosis.” |
| Degrees
Received: |
B.S., Biochemistry,
Worcester Polytechnic Institute, May 2004 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2007, University of Connecticut Pharmacy
Pre-Doctoral Award; 2004, President’s MQP Award, Salisbury
Prize; 2004-2000, Dean’s List; 2001-2000, C. Thompson Scholar |
| AFPE
Award: |
AFPE 21st
Century Club Alumni & Friends - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
ANDREA L. KJOS |
University
of Minnesota College of Pharmacy |
| Major: |
Social &
Administrative Sciences |
| GPA: |
3.86/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
Determine
how patients use both professional and lay social networks to
obtain medication information, including a critical examination
of the structure, content, and function of social networks in
the context of the medication use process among patients. The
goal of this research is to contribute to the base of knowledge
of consumer health information-seeking behavior, patient participatory
behavior, patient decision-making, and patient-provider communication.
Knowledge gained in this research may contribute to patient empowerment
initiatives, improvements in patient-provider communication, and
prevention of negative medication outcomes. |
| Title
of Dissertation: |
“Medication
Information Seeking Behavior: The Role of Social Networks" |
| Degrees
Received: |
Pharm.D.,
Drake University, May 2005 |
| Honors
Received: |
2007 AFPE
Pre-Doctoral Fellowship; 2006, APhA-APRS Postgraduate Officer
'09-'07; 2004-1999, Presidential Scholarship; 2003, CVS Scholarship;
2003-99, Dean’s List; 2002, Walgreens Scholarship; 2001
Harold Salisbury Scholarship; 1999, Harold Salisbury Scholarship;
1998, Gold Award – Girl Scouts of America |
| AFPE
Award: |
CVS Caremark
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
MICHAEL KOCH |
University
of Utah College of Pharmacy |
| Major
|
Pharmacology/Toxicology |
| GPA:
|
3.92/4.0 |
| Graduation
Date: |
December
2008 |
| Focus
of Research: |
Elucidation
of the mode of action of exocarpic acid, a naturally occurring
plant-derived polyacetylenic fatty acid, against Mycobacterium
tuberculosis and its future use as a pharmacophore for the treatment
of diseases caused by mycobacteria. This research reflects the
increasing interest in discovery of new antibacterials based on
natural products with novel molecular targets in order to increase
our repertoire of drugs against highly resistant strains of pathogenic
bacteria. |
| Title
of Dissertation: |
“Mode
of Action of Exocarpic Acid Against Mycobacterium Tuberculosis” |
| Degrees
Received: |
MSPH, Public
Health, University of Utah, December 2003
M.S., Biology, University of Michigan, December 1997
B.S., Microbiology, Weber State University, June 1994 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 1994, Valedictorian, School of Science,
Weber State University; 1993, Outstanding Foreign Student Award
& Scholarship, Dean’s List; 1991-1990, Department Service
Award |
| AFPE
Award: |
Accreditation
Council for Pharmacy Education - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
DAVID S. LEE |
Virginia
Commonwealth University School of Pharmacy |
| Major: |
Pharmacokinetics/Metabolism |
| GPA: |
3.78/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To examine
age-dependent effects on sensitivity to cholinesterase inhibitor.
The in-vitro pharmacokinetics and pharmacodynamics will be studied
in young and elderly adults to estimate sensitivity differences.
Our research hypothesis is that young adults are more sensitive
to cholinesterase inhibitor than elderly adults. Highly sensitive
adults are more prone to adverse effects while low sensitive adults
may require higher doses. Cholinesterase inhibitors are a structurally
diverse group of compounds with different physiochemical properties
that act in diverse mechanisms and have a low therapeutic index.
This research is interested in choosing the appropriate clinical
dose for low therapeutic index compounds with diverse pharmacologic
action. |
| Title
of Dissertation: |
“Sensitivity
of Cholinesterase Inhibitors in Healthy Young and Elderly Adults:
An in-vitro Pharmacokinetic and Pharmacodynamic Study of Physostigmine,
Pyridostigmine, Donepezil and Galantamine" |
| Degrees
Received: |
B.S., Chemistry,
Georgia Institute of Technology, December 1999 |
| Honors
Received: |
2007 , AFPE
Pre-Doctoral Fellowship; 2006, Thacker Award; 2005-2002, School
of Pharmacy Dean’s List; 2003, Rho Chi Induction, “Best
Poster Award” |
| AFPE
Award: |
Daiichi-Sankyo
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
KATRINA W. LEXA |
University
of Michigan College of Pharmacy |
| Major: |
Medicinal/Pharmaceutical
Chemistry |
| GPA: |
3.87/4.00 |
| Graduation
Date: |
May 2011 |
| Focus
of Research: |
To utilize
computational chemistry and knowledge of molecular dynamics to
understand allosteric control in proteins and how it could be
used to control functionality in novel ways with small molecules.
By exploring the inhibition of protein flexibility and motion
through the exertion of allosteric modulation, the research goal
is to find new mechanisms for inhibition of Human Immunodeficiency
Virus-1 protease (HIV-1p). Research has shown that activity of
the binding site can be affected through the control of protein
flexibility. Molecular dynamics allows for the exploration of
a protein’s preferred conformational states and the possible
interactions between a protein and a ligand. By incorporating
flexibility into our analysis of protein-ligand interactions,
we have the opportunity to discover novel binding sites. |
| Title
of Dissertation: |
“"Allosteric
Control of HIV-1 Protease Through Protein Flexibility and Structure-Based
Drug Design" |
| Degrees
Received: |
B.A., Cum
Laude, Chemistry and Public Policy, Hamilton College, May 2005 |
| Honors
Received: |
2008-2007,
Pharmaceutical Sciences Training Program; 2006-2005, School of
Public Health Dean's Fellowship, Elihu Root Fellowship; 2005 Judge
John Wells Fellowship, Undergraduate Research Award |
| AFPE
Award: |
AFPE 21st
Century Club Alumni & Friends - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
ANN-MARIE G. MATEI |
St.
John’s University School of Pharmacy |
| Major
|
Pharmacology/Toxicology |
| GPA:
|
3.90/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To investigate
the effects of ziram, a dithiocarbamate compound, on rat hippocampal
astrocytes in order to compare these changes and effects with
a similar type of compound and to examine the role transition
metals may play in ziram induced cytotoxicity. The research may
elucidate a mechanism for this type of injury as well as recovery.
Dithocarbamates, such as ziram, have been reported to cause several
adverse effects including neurobehavioral effects as well as neuropathological
changes. Elucidating their mechanism may help prevent these effects. |
| Title
of Dissertation: |
“The
Toxicological Effects of the Dithiocarbamate Compounds on Rat
Hippocampal Astrocytes” |
| Degrees
Received: |
M.S., Toxicology,
St. John’s University, May 2003
B.S., Pharmacy, St. John’s University, May 1996 |
| Honors
Received: |
2008, Invitro
& Alternative Methods Student Award; 2007, AFPE Pre-Doctoral
Fellowship; 2003, Rho Chi Honor Society; 1995, Dean’s List;
1992-91, Excellence Scholarship |
| AFPE
Award: |
The Merck
Company Foundation Endowed - AFPE Pre-Doctoral Fellowship in the
Pharmaceutical Sciences |
BETH M. MILLS |
University
of Iowa College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
December
2008 |
| Focus
of Research: |
To study
interactions between cationic antimicrobial peptides, which have
been found to be instrumental in the clearance of infections,
and polyanion-based therapeutics and glycosaminoglycans. The hypothesis
is that specific endogenous glycosaminoglycans and exogenous sulfated
polysaccharide therapeutics are direct and indirect effectors
of specific cationic antimicrobial peptides. The research will
evaluate glycosaminoglycans and polyanion-based therapeutics for
inhibition of antimicrobial activity and for binding affinity
for cationic antimicrobial peptides to help clarify the role that
glycosaminoglycans and polyanionic therapeutics play in modulating
the activity of these important immune system components. The
potential of polyanionic saccharides is now being recognized and
clinical trials are evaluating their HIV, microbial, and anti-cancer
activities |
| Title
of Dissertation: |
“Modulation
of Human Antimicrobial Peptides by Endogenous Glycosaminoglycans
and Saccharide-Based Therapeutics” |
| Degrees
Received: |
B.S., Microbiology
& Biochemistry, Iowa State University, May 2004 |
| Honors
Received: |
2007, AFPE
Pre-doctoral Fellowship; 2006, AFPE Pre-doctoral Fellowship; 2006,
NMCS Meeting Travel Grant; 2004, University of Iowa MNPC Fellowship,
BBMB Department Senior Award, Phi Beta Kappa Honor Society Membership;
2002, Shillinglaw Memorial Scholarship; 2001, Golden Key National
Honors Society Membership, Phi Kappa Phi Honor Society Membership;
1999, State of Iowa Scholar |
| AFPE
Award: |
Ernest Mario
Endowed - - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
REBECCA L. NEAL |
Mercer
University College of Pharmacy and Health Sciences |
| Major
|
Pharmaceutics |
| GPA: |
3.88/4.00 |
| Graduation
Date: |
May 2011 |
| Focus
of Research: |
To fully
describe and define the precise intracellular mechanism of action
employed by the recently discovered G protein-coupled receptor
(GPCR) GPR120. Previous publications have shown that stimulation
of GPR120 with long chain unsaturated free-fatty acids (FFA) causes
a potent release of glucagon-like-peptide 1 (GLP-1), which in
turns promotes release of insulin. Hence, based on this significant
pro-insulinotropic effect, GPCR120 has received a great deal of
attention as a possible target for treatment of diabetes. However,
very little is known about the intracellular signaling of GPR120,
including the mechanisms by which it facilitates GLP-1 secretion,
or the mechanisms by which the receptor is desensitized following
activation by agonists. The research project will characterize
these intracellular signaling events, with emphasis placed on
desensitization and internalization of GPR120. Our goal is to
tie a receptor to a physiological function in hopes of exploiting
it to increase endogenous insulin release |
| Title
of Dissertation: |
“Pharmacological
Characterization of the Recently Discovered Pro-Insulinotropic
Free-Fatty Acid Receptor GPR120" |
| Degrees
Received: |
B.S., Biology,
Berry College, May 2005 |
| Honors
Received: |
2007, Dean
Scholarship Award, Patrick J. Desouza, UCB Inc. Scholarship; 2005-2001,
Academic Scholarships (undergraduate); 2004, NSF-REU Summer |
| AFPE
Award: |
Novo Nordisk
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
MATTHEW S. PALOMBO |
Rutgers
University Ernest Mario School of Pharmacy |
| Major
|
Pharmaceutical
Sciences |
| GPA:
|
3.78/4.00 |
| Graduation
Date: |
May 2010 |
| Focus
of Research: |
To design
multi-functional nanoconjugates that will actively target susceptible
HIV cells to compete for viral binding by utilizing the same co-receptors
for cellular entry as HIV and will deliver effective therapeutic
agents directly to HIV infected cells. If successful, HIV mimetic
nanoconjugates will overcome current shortcomings in HIV therapies
by targeting only the cells infected by the HIV virus and not
the entire general cell population that is passively targeted
by current HIV therapies. |
| Title
of Dissertation: |
“HIV
Mimetic Nanoconjugates" |
| Degrees
Received: |
B.S. Magna
Cum Laude, Engineering, Biomedical Engineering, Tulane University,
May 2005 |
| Honors
Received: |
2005, Biomedical
Engineering Departmental Honors; 2005-2001, Dean's List; 2001,
Founders Scholarship, Son's of Italy of Atlantic County Scholarship |
| AFPE
Award: |
Josiah Kirby
Lilly Sr. Memorial - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
RYAN E. PAVLOVICZ |
Ohio
State University College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
3.85/4.00 |
| Graduation
Date: |
June 2010 |
| Focus
of Research: |
To increase
the accuracy and efficiency of simulations of physical phenomenon
at molecular, atomic, and electronic levels so that new drug-like
compounds may be discovered and optimized. More specifically,
the research will investigate the means by which particular compounds
act as nicotinic acetylcholine receptor antagonists in order to
design more potent and subtype-selective drugs for the treatment
of various neurological disorders |
| Title
of Dissertation: |
“Computational
Discovery, Evaluation, and Design of Nicotinic Acetylcholine Receptor
Antagonists" |
| Degrees
Received: |
B.S., Cum
Laude, Electrical Engineering Honors Program, Ohio State University,
June 2004 |
| Honors
Received: |
2002, Gee
Memorial Scholarship; 2001, Engineering Dean's Award; 1999, University
Scholarship Award, Babcock & Wilcox Engineering Scholarship |
| AFPE
Award: |
Procter &
Gamble - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
MATTHEW D. SCHMIDT |
University
of Iowa College of Pharmacy |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA:
|
3.72/4.00 |
| Graduation
Date: |
August 2009 |
| Focus
of Research: |
To use various
aspects of natural product isolation, medicinal chemistry, organic
synthesis, and pharmacology to explore central nervous system
(CNS) active agents. Some of the research centers around the development
of new compounds with altered levels of tolerance and dependence
which could be desirable therapeutics and/or potential treatments
for drug abuse. Much of my current work is centered on the development
of novel analgesics, antidepressants, and drug abuse therapeutics. |
| Title
of Dissertation: |
“Isolation,
Synthesis and Pharmacological Evaluation of Novel Nicotinic Acetylcholine
Receptor Ligands Based on Gedunin, a Limonoid Found in Azadirachta
Indica” |
| Degrees
Received: |
B.S., Chemistry;
B.S., Biology; B.S., Pre-Pharmacy, May 2004 |
| Honors
Received: |
2008, National
Medicinal Chemistry Symposium Travel Award; 2007, American Society
of Pharmacognosy Outstanding Poster Presentation Award, National
Scholars Honor Society Inductee; 2007, AFPE Pre-Doctoral Fellowship;
2006, AFPE Pre-Doctoral Fellowship; 2006, NIH Biotechnology Training
Grant; 2006-2005, Chancellor’s List; 2005, Center for Biocatalysis
and Bioprocessing Pre-Doctoral Fellowship; 2004, UW-Stevens Point
Student Research Fund Grant; 2003, UW-Stevens Point Student Research
Fund Grant, University Leadership Award; 2002, Pucci Family Biology
Scholarship |
| AFPE
Award: |
Consumer
Healthcare Products Association (CHPA) - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
RYAN A. SCHNEIDER |
Ohio
State University College of Pharmacy |
| Major
|
Pharmacology/Toxicology |
| GPA:
|
3.96/4.00 |
| Graduation
Date: |
June 2010 |
| Focus
of Research: |
To create
pharmacological agents called synthetic disintegrins which target
integrin receptors on endothelial cells. Tegrin receptors have
been shown to be upregulated on tumor vasculature with pharmacological
agents. These pharmacological agents could potentially be used
to manipulate/disrupt tumor vasculature and improve drug delivery
of traditional chemotherapeutic agents. Selectively targeting
the tumor vasculature could be exploited alone or in combination
with other therapeutic agents to improve cancer therapy. |
| Title
of Dissertation: |
“The
Role of Synthetic Disintegrins in Modulating Tumor Vasculature” |
| Degrees
Received: |
Pharm.D.,
Ohio Northern University, May 2005 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2007, Patil Fellowship in Pharmacology;
2005, Phi Lambda Sigma – GlaxoSmithKline-AFPE First Year
Graduate Fellowship, 2004, Mylan Excellence in Pharmacy Award;
2004, Charles Oren Lee Prize in Pharmacy Award; 2003, Merck Fellowship
for Undergraduate Research, AFPE Gateway to Research Scholarship,
Ohio Pharmacists Association Leadership Award |
| AFPE
Award: |
American
Pharmacists Association (APhA) - AFPE Pre-Doctoral Fellowship
in the Pharmaceutical Sciences |
ANNA L. SCOTT |
University
of Southern California School of Pharmacy |
| Major: |
Pharmacology/Toxicology |
| GPA: |
3.8/4.0 |
| Expected
Graduation: |
May 2009 |
| Focus
of Research: |
To investigate
the environmental and genetic basis for neurodevelopmental and
behavioral abnormalities. The neurogenetic and molecular basis
of behavior is an area of increasing interest in the study for
new medicines and researchers are seeking to determine how drugs
used to modify behavior, such as antidepressants, affect neural
stem cell proliferation. |
| Title
of Dissertation: |
“Monoamine
Oxidase Regulation of Neural Stem Cells” |
| Degrees
Received: |
B.S., Biology,
Westmont College, August 2004 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2007-2005, Dean’s Fellowship; 2003-2001,
Presidential Scholarship |
| AFPE
Award: |
Wyeth- AFPE
Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
KATHERINE THEKEN |
University
of North Carolina at Chapel Hill School of Pharmacy |
| Major
|
Pharmaceutical
Sciences |
| GPA:
|
N/A, program
uses H/P/L system |
| Graduation
Date: |
May 2011 |
| Focus
of Research: |
To investigate
whether inflammation disrupts the functional balance between the
CYP epoxygenase and omega-hydroxylase pathways in the cardiovascular
system in vivo, and whether inhibition of 20-hydroxyeicosatetraenoic
acid formation and epoxyeicosatrienoic acid by hydrolysis restores
this balance and attenuates inflammation in preclinical models
relevant to atherosclerosis in humans. Inflammation is a key component
of atherosclerotic cardiovascular disease and elevated levels
of systemic (C-reactive protein, interleukin-6) and cardiovascular-specific
(E-selectin) inflammatory biomarkers have been associated with
disease progression and mortality. The goal of the research is
to characterize the effect of inflammation on CYP-mediated arachidonic
acid metabolism in the cardiovascular system in vivo and to determine
whether modulation of these pathways represents a novel therapeutic
strategy for atherosclerosis. |
| Title
of Dissertation: |
“The
Role of Cytochrome P450-mediated Eicosanoid Metabolism in Atherosclerotic
Cardiovascular Disease" |
| Degrees
Received: |
Pharm. D.,
Pharmacy, University of Pittsburgh, April 2006 |
| Honors
Received: |
2008, AFPE
Pre-Doctoral Fellowship; 2007-2006, Schering-Plough Rho Chi AFPE
First-Year Graduate Student Scholarship; UNC Graduate School Merit
Assistantship; 2006-2005 Joseph Bianculli Scholarship, University
of Pittsburgh; 2006-2002, Dean's List, University of Pittsburgh,
School of Pharmacy; 2005-2004, Darbaker Scholarship, University
of Pittsburgh; 2004, Pfizer Summer Undergraduate Research Fellowship,
Joseph Bianculli Pharmacy Award, University of Pittsburgh; 2003,GEAR-UP
Summer Internship, University of Pittsburgh; 2002-2000, Dean's
List, University of Pittsburgh, College of Arts and Sciences |
| AFPE
Award: |
AstraZeneca
Pharmaceuticals - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
MARGARET M. S. THOMSON |
University
of Tennessee Health Science Center College of Pharmacy |
| Major
|
Pharmacokinetics/Metabolism |
| GPA:
|
3.86/4.0 |
| Graduation
Date: |
December
2010 |
| Focus
of Research: |
The research
project will focus on the disposition of drugs, particularly drug
transport, in the pediatric patient population. The goal is to
develop drug transporters and determine their role in the drug
transport process in order to better predict which drugs may be
safely given to children at various ages. |
| Title
of Dissertation: |
“
The Ontogeny of Hepatic Drug Uptake Transporters" |
| Degrees
Received: |
Pharm. D.,
University of Tennessee College of Pharmacy, May 2007
B.A., Chemistry/Psychology, Cornell College, May 1998. |
| Honors
Received: |
2007, Joe
and Pat Johnson Scholarship, AAPS CPTR-section Travelship, Who's
Who in American Colleges and Universities, Imhotep Campus Leadership
Society; 2007-2003, Seldon D. Feurt Memorial Scholarship; 2006,
Plough Scholarship; 2005, Martha Robinson Scholarship, Pleasants-Tucker
Scholarship; 2003, Allen Taylor Scholarship; 1998-1994, William
Fletcher King Scholarship. |
| AFPE
Award: |
Pfizer Inc.
- AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences |
ANJANETTE J. TURBIAK |
University
of Michigan College of Pharmacy |
| Major: |
Medicinal/Pharmaceutical
Chemistry |
| GPA: |
4.21/4.30 |
| Expected
Graduation: |
April 2010 |
| Focus
of Research: |
To design
and synthesize potential new antagonists of the beta catenin/Tcf4
complex, which is invariably upregulated in colon cancer. The
potential agonists being synthesized comprise a series of pyrimidotriazinediones,
pyrimidopyridazinediones, pyrrolopyrimidinediones, and pyrazolopyrimidinediones,
with the pyrimidotriazinediones currently being the most active.
In addition to the organic synthesis of these compounds, the research
project will also involve the development and implementation of
two in vitro assays for assessing the activity of the compounds
synthesized. This research is a classic medicinal chemistry study
geared to developing a high-throughput screen hit into a potential
drug candidate. Optimization of the lead structure is being attempted
through core manipulation to affect redox properties as well as
substituent additions and replacements to improve both activity
and pharmacokinetic properties. |
| Title
of Dissertation: |
“Synthesis
and Characterization of Novel Antagonists of the B-Catenin/Tcf4
Interaction" |
| Degrees
Received: |
M.S., Chemical
Engineering, Carnegie Mellon University, December 2004,
M.S., Organic Chemistry, University of Notre Dame, August 1997,
B.S., Chemistry, University of Notre Dame, January 1997. |
| Honors
Received: |
2007, Pharmacological
Sciences Training Grant (PSTP); 2004, Outstanding Graduate Teaching
Award; 2003, NSF Graduate Research Fellowship; 2002, Bayer Graduate
Research Fellowship, Carnegie Mellon McCabe Graduate Fellowship;
2001, WSU-SOM Dr. Morris S. Brent Award; 1997, NSF Graduate Research
Fellowship; 1997, NDSEG Fellowship, USA Today All-American Academic,
Honorary Mention, Notre Dame Outstanding Senior Chemist Award;
1997, NSF Graduate Research Fellowship; 1996, Barry M. Goldwater
Scholarship |
| AFPE
Award: |
Generic Pharmaceutical
Association (GPhA - Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
AMY E. WALTHOUR |
University
of Georgia College of Pharmacy |
| Major
|
Social &
Administrative Sciences |
| GPA:
|
4.0/4.0 |
| Graduation
Date: |
August 2009 |
| Focus
of Research: |
To analyze
outcome measures data to determine the impact of policy changes
on outcomes for patients being treated with an atypical anti-psychotic
medication within the GA Medicaid program. Rapidly rising costs
associated with pharmacy benefits within the Georgia (GA) Medicaid
program led the GA Department of Community Health to implement
cost-control measures in the GA Medicaid program. These measures
were based on clinical recommendations from the GA Drug Utilization
Review Board and practicing psychiatrists. Policy changes aimed
at reducing costs while maintaining quality of care occurred in
August 2004 for the atypical anti-psychotics class of drugs. Since
implementation of these changes, outcome measures such as total
payments, total costs and number of prescriptions, hospital admission
rates, average length of hospital encounters, emergency department
visits, physician office visits, loss of Medicaid eligibility
due to incarceration, etc. have been collected and monitored on
a quarterly basis by the GA Department of Community Health. |
| Title
of Dissertation: |
“Outcomes
Associated with State-Level Health Policy Changes for the Atypical
Anti-psychotics Class Drugs within the Georgia Medicaid Population” |
| Degrees
Received: |
B.S., Biology,
Kennesaw State University, May 2002
A.S., Chemistry, Chattanooga State Technical College, August 2000 |
| Honors
Received: |
2007, AFPE
Pre-Doctoral Fellowship; 2006, Rho Chi Inductee; 2002, Outstanding
Biology Major, Outstanding Senior in Biology, Outstanding Oral
Presentation; 2001, President’s Award – ASM; 2000,
Chemistry Merit Award, Student Excellence Award, 1999, American
Chemical Society's Regional Outstanding Student in Chemistry Award. |
| AFPE
Award: |
American
Association of Colleges of Pharmacy (AACP) - AFPE Pre-Doctoral
Fellowship in the Pharmaceutical Sciences |
ALAN B. WATTS |
University
of Texas at Austin College of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
3.84/4.00 |
| Graduation
Date: |
May 2009 |
| Focus
of Research: |
To investigate
a novel tacrolimus formulation for pulmonary drug delivery in
lung transplant and asthma models. This formulation provides a
unique opportunity to deliver local immunosuppressive therapy
to patients without causing systemic side effects associated with
blood levels. Using rapid freezing technology, it is hypothesized
that a nanostructured composition of tacrolimus can be made with
enhanced solubility and potential for increased bioavailability,
targeted delivery, and reduced systemic toxicity. |
| Title
of Dissertation: |
“Efficacy
and Tolerability of Novel Immunosuppressive Formulations for Local
Delivery to the Lungs in Lung Transplant and Asthma Therapies" |
| Degrees
Received: |
B.S., Cum
Laude, Biomedical Engineering, Louisiana Tech University, May
2003. |
| Honors
Received: |
2003, Who's
Who among American Colleges and Universities; 2002, Alpha Eta
Mu Beta; 2001, Elfervig Scholarship, Golden Key Honor Society |
| AFPE
Award: |
American
Association of Pharmaceutical Scientists (AAPS) - AFPE Pre-Doctoral
Fellowship in the Pharmaceutical Sciences |
KUANGSHI WU |
University
of Utah College of Pharmacy |
| Major
|
Pharmaceutics |
| GPA:
|
3.95/4.00 |
| Graduation
Date: |
June 2010 |
| Focus
of Research: |
To explore
the use of stimuli-sensitive materials as drug carriers that can
release a drug in a predetermined fashion at their site of action
via different administration routes (oral, IV, etc.). The research
seeks to develop hybrid carriers for protein drugs that can self-assemble
into hydrogels that can control drug release after subcutaneous
administration. Protein domains will be grafted onto the polymeric
backbones to construct stimuli-sensitive hybrid hydrogels via
coiled-coil formulation. These gels will function as a reservoir,
adjusting drug release upon physiological changes, and as shelters
protecting protein drugs from enzymatic degradation. |
| Title
of Dissertation: |
“Hybrid
Hydrogels Self-assembled from HPMA Copolymers Containing Coiled-Coil
Grafts” |
| Degrees
Received: |
M.S., Pharmaceutics,
Peking University Health Science Center, July 2003
B.S., Pharmacy, Peking University Health Science Center, July
2000 |
| Honors
Received: |
2007, AFPE
Pre-doctoral Fellowship in Pharmaceutical Science; 2002, Student
of Excellence, Peking University; 2000, Excellent Undergraduate
Thesis, Peking University Health Science Center |
| AFPE
Award: |
Ernest Mario
Endowed - AFPE Pre-Doctoral Fellowship in the Pharmaceutical Sciences
|
